Gökçe O, Gökçe C, Günel S, Ozden A, Hüseyinoğlu K, Uçar O, Güngen Y
Department of General Surgery, Firat University School of Medicine Elaziğ, Turkey.
World J Surg. 1993 Jan-Feb;17(1):94-9; discussion 99-100. doi: 10.1007/BF01655716.
Nicardipine is a relatively new calcium channel blocker with important properties that could result in attenuation of the adverse proliferative changes in autogenous vein bypass grafts. In this experimental, randomized, controlled study, the effect of nicardipine on the pathologic findings in aortoaortic bypass graft was assessed. Forty-two male rabbits (Orycytolagus cuniculus) were randomized to three groups: group 1 received nicardipine and groups 2 and 3 placebo for 4 weeks, after which an aortaortic bypass was realized with an autogenous inferior vena cava segment. During the following 4 weeks, groups 1 and 2 received nicardipine, and placebo was continued in group 3. The animals were sacrificed at the end of the study to permit removal and evaluation of the bypass grafts. The mean intimal and medial thickness values for groups 1 and 2 were lower than those for group 3, indicating that nicardipine has a significant preventive effect on the hyperplastic changes in venous bypass grafts compared to placebo. The mean intimal and medial thickness values of group 1 were also lower than those of group 2, and the differences carried statistical relevance, suggesting that the use of nicardipine before grafting could potentiate its protective effect. To provide stimulus for further research, an attempt is made to relate the hyperplasia-preventing effect of nicardipine to possible mechanisms.
尼卡地平是一种相对较新的钙通道阻滞剂，具有重要特性，可能会减轻自体静脉搭桥移植物中不利的增殖性变化。在这项实验性、随机、对照研究中，评估了尼卡地平对主动脉-主动脉搭桥移植物病理结果的影响。42只雄性家兔（穴兔）被随机分为三组：第1组接受尼卡地平治疗，第2组和第3组接受安慰剂治疗，为期4周，之后用自体下腔静脉段进行主动脉-主动脉搭桥。在接下来的4周内，第1组和第2组接受尼卡地平治疗，第3组继续使用安慰剂。在研究结束时处死动物，以便取出并评估搭桥移植物。第1组和第2组的平均内膜和中膜厚度值低于第3组，这表明与安慰剂相比，尼卡地平对静脉搭桥移植物的增生性变化具有显著的预防作用。第1组的平均内膜和中膜厚度值也低于第2组，且差异具有统计学意义，这表明在移植前使用尼卡地平可能会增强其保护作用。为了为进一步研究提供动力，人们试图将尼卡地平的增生预防作用与可能的机制联系起来。
